SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-03-0932. This Article Full Text (PDF) All Versions of this Article: 2002-03-0932v1 101/6/2426    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Rhenen, D. Articles by Corash, L. Search for Related Content PubMed PubMed Citation Articles by van Rhenen, D. Articles by Corash, L. Social Bookmarking                   What's this? Submitted March 25, 2002 Accepted October 26, 2002 Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial Dick van Rhenen, Hans Gulliksson, Jean-Pierre Cazenave, Derwood Pamphilon, Per Ljungman, Harald Klueter, Hans Vermeij, Mies Kappers-Klunne, Georgine de Greef, Michel Laforet, Bruno Lioure, Kathryn Davis, Staphane Marblie, Veronique Mayaudon, Jocelyne Flament, Maureen Conlan, Lily Lin, Peyton Metzel, Don Buchholz, and Laurence Corash* Sanquin Blood Bank South West Region, Rotterdam, The Netherlands Huddinge University Hospital, Stockholm, Sweden Etablissement Francais du Sang EFS-Alsace, Strasbourg, France Institute for Transfusion Science, Bristol, United Kingdom Institute for Transfusion Medicine and Immunology, University of Heidelberg, Faculty of Clinical Medicine, Mannheim, Germany Erasmus Medical Center, Rotterdam, The Netherlands Cerus Corp., Concord, CA, USA University of Washington, Seattle, WA, USA Baxter Healthcare Corp., Deerfield, IL, USA * Corresponding author; email: larry_corash{at}ceruscorp.com. Background: A nucleic acid targeted photochemical treatment (PCT) using amotosalen HCl (S-59) and ultraviolet (UVA) light was developed to inactivate viruses, bacteria, protozoa, and leukocytes in platelet components. Methods: We conducted a controlled, randomized, double-blinded trial in thrombocytopenic patients requiring repeated platelet transfusions for up to 56 days of support to evaluate the therapeutic efficacy and safety of platelet components prepared with the buffy coat method using this pathogen inactivation process. Results: One hundred and three patients received one or more transfusions of either PCT-Test (311 transfusions) or conventional-Reference (256 transfusions) pooled, leukoreduced platelet components stored for up to 5 days before transfusion. Greater than 50% of the PCT platelet components were stored for 4 to 5 days prior to transfusion. The mean 1-hour corrected count increment for up to the first eight Test and Reference transfusions was not statistically significantly different between treatment groups (13,100 ± 5,400 vs. 14,900 ± 6,200, p = 0.11). By longitudinal regression analysis for all transfusions, equal doses of Test and Reference components did not differ significantly with respect to the 1-hour (95% CI: -3.1 to 6.1 x 109/L, p=0.53) and 24-hour post-transfusion platelet count (95% CI: -1.3 to 6.5 x 109/L, p = 0.19). Platelet transfusion dose, pre-transfusion storage duration, and patient size were significant covariates (p<0.001) for post-transfusion platelet counts. Clinical hemostasis, hemorrhagic adverse events, and overall adverse events were not different between the treatment groups. Conclusions: Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-L. H. Kerkhoffs, J. C. Eikenboom, M. S. Schipperus, R. J. van Wordragen-Vlaswinkel, R. Brand, M. S. Harvey, R. R. de Vries, R. Barge, D. J. van Rhenen, and A. Brand A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma Blood, November 1, 2006; 108(9): 3210 - 3215. [Abstract] [Full Text] [PDF] P. D. Mintz, N. M. Bass, L. D. Petz, R. Steadman, M. Streiff, J. McCullough, S. Burks, D. Wages, S. Van Doren, and L. Corash Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease Blood, May 1, 2006; 107(9): 3753 - 3760. [Abstract] [Full Text] [PDF] J. McCullough, D. H. Vesole, R. J. Benjamin, S. J. Slichter, A. Pineda, E. Snyder, E. A. Stadtmauer, I. Lopez-Plaza, S. Coutre, R. G. Strauss, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Blood, September 1, 2004; 104(5): 1534 - 1541. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020